Double layer spherical nanoparticles with hyaluronic acid coating to enhance oral delivery of exenatide in T2DM rats
3 Pharmacotherapeutic potential of GIP and GLP-1 3.1 Therapeutic potential in T2DM Despite being the first identified incretin, GIP was initially disregarded as a viable therapeutic approach for T2DM
Alzheimers Disease: Early research indicates that GLP-1s may support brain health by reducing inflammation and oxidative stress
What Happens at PA Renewal
These conversations examine purchasing priorities, product adoption, operational challenges, approval requirements, competitive positioning, and the factors that influence wider market acceptance
All controlled studies referenced below were conducted in cell culture (3T3-L1 adipocytes, primary muscle stem cells) or rodent models (diet-induced obese mice, aged C57BL/6J mice)